Generative models are increasingly used to model adaptive immune receptor repertoire (AIRR) sequence distributions, promising to decode the sequence diversity shaping immune responses and accelerate the design of therapeutic antibodies and T-cell receptors. Yet it remains unclear whether these models produce biologically meaningful outputs or merely capture surface-level sequence statistics while missing features driven by receptor generation and selection. Rigorous evaluation is needed, but the field lacks established standards, as existing machine learning metrics do not all translate directly to the AIRR domain, given the complex structure of the data and the lack of biological ground truth. Consequently, researchers face difficulties in evaluating the models and selecting appropriate ones, which can critically affect downstream clinical applications. Here, we apply a suite of evaluation metrics tailored to AIRR sequence data and present a systematic comparison of popular generative model families proposed for the AIRR field, including variational autoencoders, long short-term memory networks, antibody language models, selection models, and simple statistical baselines. We focus specifically on the task of learning individual-specific immune receptor repertoires, a clinically relevant challenge with direct implications for personalized immunotherapy, disease monitoring, and vaccine response studies. By analyzing the sequences generated by each model, we identify memorization risks, innovation capabilities, and sensitivity to hyperparameter tuning. Taken together, these results advance the understanding of how current generative models reproduce the biology of individual immune repertoires and lay the groundwork for more principled model development and evaluation.
Charlotte Würtzen, Maria Mamica, C. Kanduri et al.· bioRxiv· 0 citations
Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase in breast cancer and other malignancies. A subset of HER2-positive tumours expresses 611-CTF-p95HER2, a tumour-specific, hyperactive truncated isoform associated with metastasis and treatment resistance that lacks most of the extracellular domain targeted by conventional HER2-directed antibodies. We previously developed NAZ-mAb (formerly known as Oslo-2), a monoclonal antibody against 611-CTF-p95HER2. Here, we describe a computational antibody-engineering workflow for designing variants of NAZ-mAb. Starting from the sequence alone, we modeled the NAZ-mAb–611-CTF-p95HER2 complex, generated a combinatorial mutational landscape using FoldX 5.0, and prioritized candidate variants using predicted interaction energy and developability criteria. Two variants representing distinct design strategies were selected for validation: an aromatic double mutant, NAZ-mAb v1 (L:S31W/L:H107W), and a conservative single mutant, NAZ-mAb v2 (L:S31M). Both variants were successfully expressed as recombinant IgGs; NAZ-mAb v2 achieved a five-fold higher recombinant expression yield than parental NAZ-mAb, while both variants retained antigen binding with a higher apparent signal than the parental antibody in indirect ELISA. However, Biacore two-state kinetic analysis revealed weaker affinities than the parental antibody (KD NAZ-mAb v1: 32.6 nM, NAZ-mAb v2: 9.45 nM vs. parental NAZ-mAb: 5.33 nM). These findings show that the computational workflow can generate experimentally tractable, antigen-engaging NAZ-mAb variants, while also highlighting the limitations of fixed-backbone interaction-energy ranking as a predictor of binding affinity and yield. This study provides a practical framework for computationally driven, developability-aware antibody optimization in the absence of experimental structural data.
P. Rawat, J. Kyte, Victor Greiff et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
